&lt;p&gt;Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer&lt;/p&gt;

Yan, Hui; Xiao, Hui; Zhu, Jiujun; Zhang, Jingyang; Liu, Zhenzhen

doi:10.2147/cmar.s278694

Cited by 9 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several factors could explain this difference. First, all patients included in the present study had IHC 2+/FISH-amplified breast cancers, which were confirmed to be less likely to achieve pCR than IHC 3+ breast cancers investigated in our previous study (19.3% vs. 31.4%) (12). Second, our study included a relatively large number of locally advanced Stage III patients (38/69, 55.1%) and patients with N3 stage tumors (24.6%, 17/69) and T3-4 stage tumors (21.7%, 15/69).…”

Section: Discussionsupporting

confidence: 75%

“…According to the 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines, all patients diagnosed with breast cancer should undergo HER-2 testing to formulate appropriate treatment strategies for achieving better treatment outcomes (11). Our previous study showed that patients with HER-2-positive (IHC 3+) breast cancer have significantly higher pCR rates, which indicates that the HER-2 protein expression level might serve as an independent predictor of the NAC (12). Some studies have also shown that the level of the HER-2/CEP17 (chromosome enumeration probe 17) ratio correlates with pCR rates in patients with HER-2-positive breast cancer after treatment with NAC plus trastuzumab (13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment—a retrospective cohort study

Wang¹,

Qiao²,

Ruan³

et al. 2022

Gland Surg

Self Cite

View full text Add to dashboard Cite

Background: Human epidermal growth factor receptor-2 (HER-2) protein expression level could serve as a predictor of pathological complete response (pCR) to neoadjuvant trastuzumab-containing regimens.The aim of the present study was to evaluate whether pCR to neoadjuvant trastuzumab and pertuzumab treatment is dependent on the level of the HER-2/CEP17 (chromosome enumeration probe 17) ratio in immunohistochemistry (IHC) 2+/fluorescence in situ hybridization (FISH)-amplified breast cancer.Methods: Patients with primary IHC 2+/FISH-amplified breast cancer who underwent neoadjuvant anti-HER-2 dual-targeted therapies were retrospectively included between January 1, 2020 and May 30, 2021.The primary predictive variable was HER-2/CEP17 ratio, and the primary outcome variable was pCR.Other variables consisted of age, menopausal status, tumor-node-metastasis (TNM) stage, estrogen receptor (ER), progesterone receptor (PgR), and Ki-67. Association between clinicopathologic variables and pCR was evaluated using the chi-square test and logistic regression analysis. Results:The median age of the patients was 51.78 years (25-67 years), and 50.7% of the patients were in the premenopausal stage. The clinical stage at diagnosis was Stage III in 38 patients (55.1%). Of all patients, 40.6% patients were estrogen receptor positive, and 75.4% patients had a Ki-67 index of ≥30%. The overall pCR (ypN0/isypN0) rate was 31.9%. Patients with HER-2/CEP17 ratio ≥6.0 had a pCR rate of 55.0%, it was statistically higher than 22.4% in patients with HER-2/CEP17 ratio <6.0. Logistic regression analysis confirmed the independent association between HER-2/CEP17 ratio and pCR (P=0.020, OR: 5.203, 95% CI: 1.302-20.783).Conclusions: A HER-2/CEP17 ratio ≥6.0 might be related to more achievement of pCR in the neoadjuvant anti-HER-2 dual-targeted therapies. Further studies are needed to validate the finding.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Introductionmentioning

confidence: 99%

Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment—a retrospective cohort study

Wang¹,

Qiao²,

Ruan³

et al. 2022

Gland Surg

Self Cite

View full text Add to dashboard Cite

show abstract

“…Indeed, this issue has been investigated in several retrospective studies and clinical research, which may ultimately help to guide clinical treatment strategies. 28 , 29 …”

Section: Discussionmentioning

confidence: 99%

Clinical and Therapeutic Factors Vary by Prognosis in Patients with Pathological Complete Response After Neoadjuvant Therapy for Breast Cancer

Huang¹,

Jin²,

Zeng³

et al. 2021

CMAR

View full text Add to dashboard Cite

Purpose To determine clinical predictors of recurrence and metastasis in patients with pathological complete response (pCR) after neoadjuvant chemotherapy (NCT). Methods Patients treated with NCT who achieved pCR (n=285) were classified into three groups according to pre-NCT clinical stage (cStage): group I (IIa–IIb), group II (IIIa), and group III (IIIb–IIIc). Survival was analysed using the Kaplan–Meier method. The relationships between clinicopathological factors and recurrence were determined using Cox regression analysis. Results The median follow-up was 31 months. The 3-year disease-free survival and overall survival rates in groups I, II, and III were 92.7%, 87.8%, and 66.7% ( P < 0.01) and 98.6%, 98.3%, and 90.6% ( P =0.370), respectively. Lymph node status and tumour size were independent risk factors for recurrence and metastasis after NCT. In the human epidermal growth factor receptor 2-positive subgroup, advanced cStage and lymph node metastasis were associated with recurrence ( P < 0.01). In the hormone receptor-positive subgroup, disease-free survival rates differed for cStages I–II compared to cStage III ( P =0.049) and clinical node status 0–2 compared to clinical node status 3 ( P =0.037). Conclusion Pre-NCT cStage predicted the prognosis of pCR for different breast cancer subtypes. Patients with advanced cStage, lymph node metastasis, and large tumour sizes had a higher risk of recurrence or metastasis.

show abstract

“…Several associations with other predictive and prognostic markers present in tumour cells of mammary cancer may be found when analyzing CAIX (Furlejova et al 2015;Alves et al 2019;Yan et al 2020). Generali et al (2006) demonstrated that CAIX positivity correlates with HER2 overexpression in the tumour tissue of human breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Histopathological and immunohistochemical analysis of predictive and prognostic markers in spontaneous canine mammary cancer

et al. 2023

View full text Add to dashboard Cite

The study investigates the interspecies similarities between canine and human mammary cancer in the sense of innovative predictive and prognostic tumour markers. Surgical resection specimens with diagnosed spontaneous primary mammary cancer obtained from 100 female canine patients were included in this study. Expression of carbonic anhydrase IX (CAIX) enzyme and human epidermal growth factor receptor 2 (HER2) expression was evaluated immunohistochemically. The study was completed with investigation of Ki67 expression and proliferation with marker of myogenous differentiation. Histopathological grading was performed using the Nottingham/modified Bloom-Richardson system. As in humans, our analysis of canine mammary cancer has shown that CAIX positivity in tumour cells significantly correlates with higher levels of HER2 immunoreactivity (P = 0.001), and increased tumour grade (P < 0.001). The percentage of smooth muscle actin (SMA) positive cases was significantly higher (P = 0.002) in the group of mammary carcinomas with CAIX positivity compared to the tumours that were negative. Using antibody Ki67 proliferative activity was not significantly different between mammary tumours that were CAIX positive and CAIX negative. Canine mammary gland carcinomas may, therefore, represent valuable animal models for the study of hypoxic signaling pathways involved in mammary carcinogenesis in humans. Further research investigating this possibility is required.

show abstract

<p>Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer</p>

Cited by 9 publications

References 30 publications

Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment—a retrospective cohort study

Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment—a retrospective cohort study

Clinical and Therapeutic Factors Vary by Prognosis in Patients with Pathological Complete Response After Neoadjuvant Therapy for Breast Cancer

Histopathological and immunohistochemical analysis of predictive and prognostic markers in spontaneous canine mammary cancer

Contact Info

Product

Resources

About